Management of hyperlipidaemia.
Recent community-based studies have shown that hypercholesterolaemia is common in Singapore. High low-density lipoprotein (LDL) cholesterol, low high-density lipoprotein (HDL) cholesterol as well as hypertriglyceridaemia are associated with higher prevalence of cardiovascular disease. The aim of this article is to discuss the clinical management of adult patients with hyperlipidaemia. For practical purposes, the hyperlipidaemias can be divided into four patterns: 1) hypercholesterolaemia with normal triglyceride, 2) moderate hypertriglyceridaemia with normal cholesterol, 3) combined moderate hypercholesterolaemia and hypertriglyceridaemia, and 4) severe hypertriglyceridaemia with moderate hypercholesterolaemia. Each pattern can be attributed primarily to genetic conditions or secondarily to common diseases. It is important to attempt aetiopathogenetic diagnosis for each hyperlipidaemic patient as treatment of an underlying condition may sometimes reverse the hyperlipidaemia eg hypothyroidism and hypercholesterolaemia. In general, a low cholesterol and low fat (particularly saturated fat) diet is useful in patients with all four patterns of hyperlipidaemia. Patients with severe hypertriglyceridaemia and moderate hypercholesterolaemia may benefit from a further drastic reduction in fat intake. Pharmacological therapy is required for patients who do not achieve target lipid levels after diet modification. The choice of drug therapy is, to a large extent, dependent on the pattern of hyperlipidaemia. In some situations, combination drug therapy may be required. Caution is required in combining hypolipidaemic drugs as the side-effects of individual drugs may be potentiated when used in combination.
Sum
C F
CF
Gleneagles Medical Centre, Singapore.
Tan
C E
CE
Chew
L S
LS
D003131:Combined Modality Therapy; D018752:Diet, Fat-Restricted; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000209:etiology / Q000628:therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008055:Lipids / Q000097:blood
D000960:Hypolipidemic Agents; D008055:Lipids